Showing results (161-170 of 279) with videos related to
Sort By:
Pageof 28
JAMA Oncology|December 13, 2019
Association Between New Unconfirmed Bone Lesions and Outcomes in Men With Metastatic Castration-Resistant Prostate Cancer Treated With Enzalutamide: Secondary Analysis of the PREVAIL and AFFIRM Randomized Clinical TrialsAndrew J Armstrong, Mohammed Al-Adhami, Ping Lin, et al.Cancer|September 20, 2013
Ixabepilone, mitoxantrone, and prednisone for metastatic castration-resistant prostate cancer after docetaxel-based therapy: a phase 2 study of the Department Of Defense Prostate Cancer Clinical Trials ConsortiumAndrea L Harzstark, Jonathan E Rosenberg, Vivian K Weinberg, et al.European Urology|May 20, 2011
New therapies for castration-resistant prostate cancer: efficacy and safetyHimisha Beltran, Tomasz M Beer, Michael A Carducci, et al.Frontiers in Oncology|August 28, 2020
Phase II Study of Ipilimumab in Men With Metastatic Prostate Cancer With an Incomplete Response to Androgen Deprivation TherapyJulie N Graff, Mark N Stein, Rishi Surana, et al.Cancer|November 10, 2025
The impact of multicancer early detection tests on cancer stage shift: A 10-year microsimulation modelJagpreet Chhatwal, Jade Xiao, Andrew K ElHabr, et al.Lancet (London, England)|October 7, 2023
Blood-based tests for multicancer early detection (PATHFINDER): a prospective cohort studyDeb Schrag, Tomasz M Beer, Charles H McDonnell, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 19, 2018
Epigenetic Therapy with Panobinostat Combined with Bicalutamide Rechallenge in Castration-Resistant Prostate CancerAnna C Ferrari, Joshi J Alumkal, Mark N Stein, et al.European Urology Focus|July 21, 2017
Targeting Adaptive Pathways in Metastatic Treatment-Resistant Prostate Cancer: Update on the Stand Up 2 Cancer/Prostate Cancer Foundation-Supported West Coast Prostate Cancer Dream TeamRahul Aggarwal, Tomasz M Beer, Martin Gleave, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 1, 2007
Sorafenib with interferon alfa-2b as first-line treatment of advanced renal carcinoma: a phase II study of the Southwest Oncology GroupChristopher W Ryan, Bryan H Goldman, Primo N Lara, et al.Cancer Research|April 15, 2010
ID1 enhances docetaxel cytotoxicity in prostate cancer cells through inhibition of p21Hao Geng, Brooks L Rademacher, Janet Pittsenbarger, et al.Pageof 28